B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024 report and make more profitable business decisions.
B-cell chronic lymphocytic leukemia is a type of slow-growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms, or in the groin; pain or discomfort under the ribs on the left side due to an enlarged spleen; frequent or repeated infections and slow healing, due to a lack of normal white blood cells; excessive sweating at night; and unintentional weight loss. Treatment includes chemotherapy and radiation.
The B-Cell Chronic Lymphocytic Leukemia drugs in development market research report provide comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – B-Cell Chronic Lymphocytic Leukemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 30 molecules, with 23 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of B-Cell Chronic Lymphocytic Leukemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed B-Cell Chronic Lymphocytic Leukemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of B-Cell Chronic Lymphocytic Leukemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AB Science SAAllarity Therapeutics Inc
Athenex Inc
Baylor College of Medicine
BeiGene Ltd
Beijing Boren Hospital
Beijing Immunochina Pharmaceuticals Co Ltd
BioInvent International AB
Biosplice Therapeutics Inc
BioXpress Therapeutics SA
Bristol-Myers Squibb Co
California Institute for Biomedical Research
Chengdu USino Technology Biology Co Ltd
CRISPR Therapeutics AG
Eli Lilly and Co
Gansu Provincial Cancer Hospital
Hangzhou Hezheng Pharmaceutical Co Ltd
ITabMed Co Ltd
Loxo Oncology Inc
ManysmarT Therapeutics Inc
Mayo Clinic
Mediolanum farmaceutici SpA
Merck & Co Inc
Nkarta Inc
Pure Biologics SA
Regeneron Pharmaceuticals Inc
Shanghai Pharmaceutical Group Co Ltd
Third Military Medical University Hospital One
Xuzhou Medical College
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more B-Cell Chronic Lymphocytic Leukemia reports